Researchers have discovered new details about the underlying mechanisms of skin hardening syndromes. The team connected pharmacological properties of the drug balicatib to the skin disorder for the first time after investigating adverse reactions suffered by patients participating in a clinical trial for the treatment of osteoporosis.